Literature DB >> 22351834

A randomized, double-blind, placebo-controlled proof of concept trial of topical cidofovir, 1% and 3%, for the prevention of beard hair growth in men.

Joy Wan, Carmela C Vittorio, Katrina Abuabara, Shanu K Kurd, Amy Musiek, Jane M Steinemann, Joel M Gelfand.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22351834      PMCID: PMC3677218          DOI: 10.1001/archdermatol.2011.1406

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


× No keyword cloud information.
  5 in total

1.  Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study.

Authors:  D Calista
Journal:  J Eur Acad Dermatol Venereol       Date:  2000-11       Impact factor: 6.166

2.  Differences in hair follicle dermal papilla volume are due to extracellular matrix volume and cell number: implications for the control of hair follicle size and androgen responses.

Authors:  K Elliott; T J Stephenson; A G Messenger
Journal:  J Invest Dermatol       Date:  1999-12       Impact factor: 8.551

3.  Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair.

Authors:  John E Wolf; Douglas Shander; Ferdinand Huber; Joseph Jackson; Chen-Sheng Lin; Barbara M Mathes; Kathy Schrode
Journal:  Int J Dermatol       Date:  2007-01       Impact factor: 2.736

Review 4.  Defining pseudofolliculitis barbae in 2001: a review of the literature and current trends.

Authors:  Patricia K Perry; Fran E Cook-Bolden; Zakia Rahman; Elena Jones; Susan C Taylor
Journal:  J Am Acad Dermatol       Date:  2002-02       Impact factor: 11.527

5.  Reliability and validity of a photographic method for measuring facial hair density in men.

Authors:  Joy Wan; Katrina Abuabara; Shanu K Kurd; Amy Musiek; Jane M Steinemann; Carmela C Vittorio; Joel M Gelfand
Journal:  Arch Dermatol       Date:  2011-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.